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Abstract
The progression and metastasis of solid tumors, including head and neck squamous cell carcinoma
(HNSCC), have been related to the behavior of a small subpopulation of cancer stem cells. Here,
we have established a highly malignant HNSCC cell line, SASVO3, from primary tumors using three
sequential rounds of xenotransplantation. SASVO3 possesses enhanced tumorigenic ability both in
vitro  and  in vivo. Moreover, SASVO3 exhibits properties of cancer stem cells, including that
increased the abilities of sphere-forming, the number of side population cells, the potential of
transplanted tumor growth and elevated expression of the stem cell marker Bmi1. Injection of
SASVO3 into the tail vein of nude mice resulted in lung metastases. These results are consistent
with the postulate that the malignant and/or metastasis potential of HNSCC cells may reside in a
stem-like subpopulation.
Introduction
Solid tumors are known to be composed of a heterogene-
ous population of cells, and it has been possible to
observe that certain cell residing inside tumors have stem
cell like properties including tumor growth (self-renewal),
heterogeneity (differentiation) and growth in tissue envi-
ronments different from the original one (metastasis)
[1,2]. The identification of this small subpopulation of
highly tumorigenic cancer cells in solid human tumors
has led to the development of the cancer stem cell theory
of tumorigenesis, which postulates that only a specific
rare subpopulation of cancer cells has the ability to sus-
tain cancer growth, and the remaining cancer cells have
only limited growth potential or perhaps no growth
potential at all [3]. Cancer stem cells possess three funda-
mental characterizations [4]. First, they have to self-renew,
allowing the maintenance of the original stem cell popu-
lation. Second, cancer stem cells must be able to differen-
tiate into multiple types of mature cells. Third, the total
number of stem cells is strictly regulated via both extrinsic
and intrinsic mechanisms. Based on these characteristics,
four key methodologies were developed to identify the
cancer stem cell subpopulation [3]: first, cancer stem cell
were enriched by sphere assay to form tumorspheres, in
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culture conditions that promote maintenance of cancer
stem cells; second, Hoechst 33342 staining used to iden-
tify the side population cell that enriches for cancer stem
cell; third, the small population of cancer stem cell can be
serially transplanted through multiple generations;
fourth, only a small portion of the cancer cells within a
tumor have tumorigenic potential when transplanted into
immunodeficient mice.
Experimental evidence for the existence of cancer stem
cells has been reported for several tumor types, including
glioma, breast, colon, prostate and HNSCC [2,5-7]. A sub-
population of cells with cancer stem cell like properties
also appear to persist in cell lines derived from a wide
range of malignancies[1,8-14], including cell lines derived
from HNSCC [12,15]. Recent studies have shown that the
initiation, progression, recurrence and metastasis of
HNSCC may involve a small population of cancer stem
cells [16-18]. In addition, cancer stem cells have been sus-
pected to be the underlying reason for the incurable and
relapsing nature of many metastatic tumors. Develop-
ment of new therapies that target these cancer stem cells
may significantly improve the clinical treatment of cancer.
Therefore, it is of importance to identify, within tumors,
the subpopulation of cells that display cancer stem cell
properties.
We have previously reported that a small population of
HNSCC cells displaying the characteristics of cancer stem
cells was enriched by sphere formation [17]. In addition,
the expression of the stem-related markers in cancer stem
cells has been shown to negatively correlate with the sur-
vival prognosis of HNSCC patients. However, the in vitro
tumor sphere method for the enrichment and isolation of
cancer stem cells may not imitate well the in vivo situation,
since maintaining a small population of cancer stem cells
in a cancer is known to require a special microenviron-
ment [19,20]. So far, the serial xenotransplantation
method is generally considered to be the gold standard for
the isolation of the small population of highly malignant
cells from a solid tumor [3]. Here, we postulated that
serial xenotransplantation of a cancer cell line in nude
mice will reduce the number of non-malignant clones
present that may have been selected during the establish-
ment of this cell line. In this study, we employed a
xenotransplatation mouse model to investigate the malig-
nant heterogeneity of the HNSCC cells.
Materials and methods
Cell Culture
The human tongue cancer cell line SAS, a high-grade tum-
origenic HNSCC cell line, was obtained from the Japanese
Collection of Research Bioresources (Tokyo, Japan).
293FT, kindly provided by Dr. W.-Y. Hu and was used for
packaging of the viral particles. Both SAS and 293FT cells
were cultured in Dulbecco's modified Eagle's medium
(DMEM) containing 10% fetal bovine serum, 1% L-
glutamine, 0.5 mM sodium pyruvate, 1.2 g/L sodium
bicarbonate, and 2.5 mM L-glutamine.
Cultivation of the cells to form tumor spheres has been
described previously [17]. In brief, the cells were cultured
in tumor sphere medium consisting of serum-free
DMEM/F-12, N2 supplement, 10 ng/mL human recom-
binant bFGF, and 10 ng/mL EGF until sphere formation
was observed at about 4 weeks. All culture medium,
chemical compounds, and fetal bovine were purchased
from Life Technologies (Grand Island, NY).
Plasmids and Transfection, preparation of lentivirus virus 
particles and infection
The pLV-EF1α-GFP lentivirus that contains the green fluo-
rescent protein (GFP) expression cassette was purchased
from Biosettia Inc. (Biosettia, San Diego, CA). pCMVD8.2
and pMD.G, which expresses GAG-POL and the vesicular
stomatitis virus envelope respectively, were provided by
the consortium (Academia Sinica, Taipei, Taiwan). Isola-
tion of all plasmid DNAs was carried out using a HiSpeed
plasmid purification kit (Q-Biogene, Carlsbad, CA, USA)
and the protocol provided by the manufacturer.
Transfection of plasmid DNA into the cells was generally
done using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) and the protocol provided by the manufacturer. The
efficiency of transfection was determined by microscopic
examination of the green fluorescence produced by the
pLV-EF1α-GFP vector.
The lentiviruses were generated by cotransfecting 293FT
with lentiviral vector and packaging plasmids at 37°C for
48 h. After transfection, the viral supernatant was har-
vested by spinning at 2000 rpm for 10 min at 4°C. The
SAS cells were inoculated with 100 μL of viral stock with
MEM medium, 10% FBS and 6 μg/μL polybrene. The
infected cells were incubated for 2 h at 37°C, washed
twice, and then cultured in complete medium until cells
were harvested. The recombinant cells were separated
using a FACS Calibur apparatus (Becton Dickinson) to
sort out the population of GFP expressing cells from the
non-transfected cells.
Antibodies and Western blotting
The antibodies used in this study include anti-Bmi1 (Cell
Signaling, Temecula, CA, USA), anti-β-Catenin (BD Bio-
sciences), anti-p14 (Santa Cruze Biotechnology, Inc.
Santa Cruz, CA, USA), anti-p21 (Santa Cruze Biotechnol-
ogy), anti-phosphorylated AKT (Ser473)(Cell Signaling,
Temecula, CA, USA), anti-AKT (Santa Cruze Biotechnol-
ogy), and anti-GAPDH (Chemicon, Temecula, CA, USA).Journal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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For Western blot, the cell pellets were homogenized in
200 μL lysis buffer (50 mM HEPES, pH 7.5, 150 mM
NaCl, 10% glycerol, 1.5 mM MgCl2, 1% Triton X-100)
and incubated on ice for 20 min. After centrifugation at
13,000 g for 30 min at 4°C, the supernatant containing
the protein extracts was collected. Protein concentrations
were determined using the Bio-Rad protein assay. Western
blot analyses were performed as described previously
[21].
Establishment of Xenograft-derived SAS cell lines
The SAS cells were infected with pLV-EF1α-GFP lentivirus
and GFP-expressing cells were collected by sorting using a
flow cytometer. All the animal practices in this study were
in accordance with the institutional animal welfare guide-
line of Taipei VGH or National Yang-Ming University, Tai-
wan. To establish the first generation xenograft-derived
SAS cell line, the GFP-expressing SAS cells (designated as
SAS-GFP in this study) were injected subcutaneously into
the dorsal flank of 6-week-old nude BALB/c nu/nu mice.
In vivo GFP imaging of the tumor was carried out and each
tumor's size measured as described previously [21]. The
solid tissue from the tumor was then mechanically and
enzymatically disaggregated into a single-cell suspension,
and this was designated SASVO1. A second generation
xenograft-derived SAS cell line was then established using
the same protocol as above, this time using cells from the
tumor produced by the SASVO1 cells; this single cell sus-
pension was designated SASVO2. Finally, a third genera-
tion xenograft-derived SAS cell line was established from
the tumor produced by SASVO2 cells, and this was desig-
nated SASVO3.
Assays of proliferation, migration, invasion, and 
anchorage-independent growth
An MTT assay kit (Sigma-Aldrich) was used to analyze the
cell proliferation. Specifically, 1 × 103 cells were seeded in
each well of a 24-well plate, and then 10 μL of MTT solu-
tion was added to the cells, which were then incubated at
37°C for 3 hours. The supernatant was removed, and 200
μL of DMSO were added directly to the cells. The MTT
color reaction was analyzed using a microplate reader set
at A560 nm.
For the migration assay, 2 × 105 cells in a medium with
low serum (0.5% FBS) were plated in the top chamber of
a Transwell (Corning, Acton, MA) with a porous transpar-
ent polyethylene terephthalate membrane (8.0 μm pore
size). Medium supplemented with high serum (15% FBS)
was placed in the lower chamber and used as a chemoat-
tractant. The cells were incubated for 24 h at 37°C and
cotton swabs were used to remove cells that did not
migrate through the pores. The cells on the lower surface
of the membrane were stained with Hoechst 33258
(Sigma-Aldrich) and fluorescent cells were identified at a
magnification of 100× using a fluorescence microscope
(Carl Zeiss, Oberkochen, Germany). The number of fluo-
rescent cells in a total of five randomly selected fields was
counted.
Invasion assays were done in 24-well Transwell units with
an 8.0 μm porous transparent polyethylene terephthalate
membrane. Cells (1 × 105 per well) were added to upper
chambers (filter coated with 1 mg/mL Matrigel) in 100 μL
of the low serum medium. The lower chambers were filled
with 500 μL high serum medium. After 24 h incubation at
37°C, cells that remained in the Matrigel or attached to
the upper side of the filter were removed with cotton
swabs. Cells that had migrated through the membrane to
the lower surface were stained with Hoechst 33258 and
counted in five different fields under a fluorescence
microscope.
For anchorage-independent growth, 5 × 104 cells were
mixed with 2 mL of MEM containing 0.35% agarose
(Sigma-Aldrich) and 0.5% FBS, and poured onto 60-mm
plastic culture dishes pre-solidified with 2 mL MEM con-
taining 0.7% agarose and 15% FBS. The plates were incu-
bated at 37°C for 3 weeks and then stained with 0.5%
crystal violet. The number of colonies with a diameter ≥
100 μM was scored. Triplicate samples were performed for
each experiment.
Analysis of the side population that excludes Hoechst 
33342 dye
The cells were detached from the dishes and suspended at
1 × 106 cells/ml in Hanks' balanced salt solution (HBSS,
Invitrogen) supplemented with 2% fetal calf serum and
10 mM HEPES (Invitrogen). These cells were then incu-
bated at 37°C for 90 minutes with 10 g/mL Hoechst
33342 (Sigma Chemical, St Louis, MO), either alone or in
the presence of 50 g/mL verapamil (Sigma Chemical).
After incubation, the stained cells were collected by cen-
trifugation, washed, and resuspended in ice-cold HBSS.
Analysis of Hoechst 33342 efflux was performed using a
FACSc Calibur apparatus (Becton Dickinson, Milan, Italy)
with incident 350 nm ultraviolet light. The resulting fluo-
rescence was measured at two wavelengths using 424/44
BP and 675 LP filters that allow detection of Hoechst blue
and red, respectively.
In vivo tumor growth and metastasis
The tumor cells were subcutaneously injected into the
flank of six-week-old BALB/c nu/nu mice, and examined
every 5 to 7 days for tumor appearance. Tumor growth
was measured twice weekly until 28 days after inoculation
by determining the tumor volumes using the formula
(Length × Width2)/2. For the detection of metastasis, 5 ×
105 tumor cells were injected into tail vein and the mice
were sacrificed after 90 days to detect tumor colonizationJournal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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in the lung. In vivo GFP imaging of tumors was carried out
and they were then measured as described in the section
"Establishment of xenograft SAS cell lines".
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [21]. In brief, tumor specimens were fixed in for-
malin and embedded in paraffin before sectioning, or
kept frozen in optimal cutting temperature (OCT) embed-
ding media. Seven-micron sections were fixed in ice-cold
acetone for 5 min, and air-dried. The sections were depar-
affinized twice in xylene for total of 10 min, rinsed in alco-
hol and then alcohol/water mixtures for 5 min with each
solution, and then treated with 3% hydrogen peroxide to
block endogenous peroxidase. After rinsing in distilled
water, antigen retrieval was done by boiling in 50 ml of 1×
Trilogy for 30 min. Then, after cooling, the sections were
rinsed in phosphate-buffered saline (pH 7.4) for another
5 min. The tissue sections were incubated overnight with
primary antibody at 4°C and then incubated with the sec-
ondary antibody for 1 hour at room temperature. Color
was developed with AEC substrate chromogen (Dako Cor-
poration, USA) for 10 min at room temperature. The same
sections were also then counterstained with 1% hematox-
ylin according to the manufacturer's suggested protocol
(Zymed Laboratories), dehydrated, and cover slipped
with Histomount (Sigma Chemical Co., USA). The sec-
tions were examined under a light microscope.
Statistics
An unpaired t-test was used for the statistical analysis. The
results were considered to be statistically different when
the p-value was < 0.05.
Results
Xenograft-derived SAS cells display increased tumor 
growth in nude mice
To test the hypothesis that serial xenotransplantation of a
cancer cell line in nude mice may enrich the malignant
subpopulation, tumor forming SAS-GFP cells were
injected subcutaneously into the dorsal flank of 6-week-
old nude BALB/c nu/nu mice, and three xenograft-derived
SAS cell lines, namely SASVO1, SASVO2 and SASVO3,
were established from the xenograft tumors (Figure 1A). It
was noted during the establishment of these xenograft-
derived cell lines that the tumors generally became palpa-
ble at 5 to 7 days after inoculation, and that the expansion
in size of the tumor produced by SASVO3 was faster than
those of either SASVO1 or SASVO2 (Figure 1B). This
would seem to indicate that the successive implantation
of SAS cells in nude mice increased the ability of the
tumor to grow.
Xenograft-derived SAS cells exhibit increased capacity for 
proliferation, migration, invasion and anchorage-
independent growth in vitro
To assess the malignancy of the xenograft-derived SAS cell
lines  in vitro, the ability of these cells to proliferate,
migrate, invade and to perform anchorage-independent
growth was examined in vitro. As shown in Figure 2, the
SASVO3 cells displayed the highest capacity for prolifera-
tion, migration, invasion and anchorage-independent
growth and this was followed by SASVO2, then SASVO1,
and finally the initial SAS-GFP cells. These in vitro results
are consistent with the increase in tumor growth observed
for the xenograft-derived SAS cells. The results indicate
that successive rounds of tumor formation in mice would
seem to have enriched for a subpopulation of cells with
higher ability for proliferation, migration, invasion and
anchorage-independent growth.
Enrichment of cancer stem cells in SASVO3
We have previously demonstrated that a subpopulation of
HNSCC cells display the characteristics of cancer stem
cells [17]. To address whether the xenograft-derived
SASVO3 cells may be enriched for such cancer stem cells,
the ability of SASVO3 cells to form tumor spheres was
examined. As shown in Figure 3A, the spheres were
formed more efficiently by SASVO3 cells (right panel), and
the size of the tumor spheres formed by SASVO3 cells was
about 3-fold larger than the ones formed by SAS-GFP cells
(left panel). To further evaluate whether SASVO3 cells
indeed are enriched for cancer stem cells, the side popula-
tion (SP) cells that contain the cancer stem cells and pos-
sesses the ability to efflux Hoechst 33342 dye was
examined [11]. As shown in Figure 3Bupper panel, around
2% of Hoechst Low SP cells were detected among the
SASVO3 cells, whereas only 0.6% of SP cells were detected
among the SAS-GFP cells. Pre-incubation with verapamil
(a calcium ion channel antagonist) for 30 min reduced
the percentage of SP cells to 0.4% among the SASVO3
cells, but effectively eliminated all of the SP cells among
the SAS-GFP cells (Figure 3B, bottom panel). Finally, the
tumorigenic potential of the new cell line was evaluated in
terms of in vivo tumor formation. As shown in Figure 3C,
while a subcutaneous injection of 1 × 103 SAS-GFP cells
produced no tumors in three mice, injection of 5 × 103
SAS-GFP cells produced a tumor in one out of three mice
at 28 days. In contrast, an injection of 1 × 103 SASVO3
cells was able to generate tumors in two out of three mice,
indicating that SASVO3 cells were enriched for cancer
stem cells by at least 5-fold. Taken together, these results
demonstrated that SASVO3 is greatly enriched in cancer
stem cells.Journal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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Establishing HNSCC cell lines with increased malignant potential by the xenograft model Figure 1
Establishing HNSCC cell lines with increased malignant potential by the xenograft model. (A) Experimental strat-
egies for the generation of HNSCC cell lines with increased malignant potential. The solid tissue from the tumors produced by 
implantation of SAS-GFP, SASVO1 and SASVO2 cells was mechanically and enzymatically disaggregated into single-cell suspen-
sion, and designated as SASVO1, SASVO2 and SASVO3, respectively. In vivo GFP imaging of the tumors was carried out and the 
tumors were measured using an illuminating device. Pictures shown are from mice at 28 day post-injection. (B) Tumor growth 
of the xenograft-derived SAS cells in the nude mice. Tumors volumes were determined twice weekly. Data shown are the 
means ± SD.Journal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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Capacity of the xenograft-derived SAS cells for proliferation, migration, invasion and anchorage-independent growth in vitro Figure 2
Capacity of the xenograft-derived SAS cells for proliferation, migration, invasion and anchorage-independent 
growth in vitro. The SAS-GFP, SASVO1, SASVO2 and SASVO3 cells were assayed for (A) proliferation capacity, (B) Tran-
swell migration ability, (C) Matrigel invasion ability and (D) anchorage independent growth as described in the Materials and 
Methods. Data shown are the means ± SD from three independent experiments. *, indicates p < 0.05; ***, indicates p < 0.001 
when analyzed with unpaired t-test.
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Identification of cancer stem cells in SASVO3 Figure 3
Identification of cancer stem cells in SASVO3. (A) Analysis of the tumor spheres generated by SASVO3 and SAS-GFP. 
The sizes (left panel) and numbers (right panel) of the tumor spheres formed by SAS-GFP and SASVO3 cells were analyzed by 
the sphere culture method as described in the Materials and Methods. Data shown are the means ± SD from three independ-
ent experiments. ***, indicates p < 0.001 when analyzed with unpaired t-test. (B) The flow cytometric profiles of side popula-
tion (SP) cells that exclude Hoechst 33342 dye in SAS-GFP (left) and SASVO3 (right). The SP cells profiles in the presence of 50 
g/mL verapmil are depicted at the bottom. The area containing SP cells is marked and shown as percentage of the total cells in 
the inset. The result is from one of three similar experiments. (C) Tumor-initiating ability of SAS-GFP and SASVO3 in the nude 
mice xenograft transplant model. The picture shown on the upper panel is from mice injected with 1 × 103 cells for 28 days.Journal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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SASVO3 cells display an increased expression of Bmi1 and 
pAKT
To address whether the cancer stem cells enriched within
SASVO3 may express molecules that are unique to stem
cells and/or malignant cells, the expression levels of Bmi1,
pAKT, CD133, CD44, Nanog, Oct-4, p21 and p14INK4A/ARF
were determined. CD133, CD44, Nanog, and Oct-4 are
known to be the common markers of cancer stem cell for
HNSCC [17,18]. Bmi1 was chosen in this study because it
has been implicated in the control of stem cells across
multiple tissues, particularly as a positive regulator in the
self renewal of hematopoietic and neuronal stem cells. It
has also been implicated in the tumorigenesis of several
cancers including leukemia [22,23], lung cancer [24],
breast cancer [25], colorectal cancer [26] and HNSCC
[27,28]. The oncogenic function of Bmi1 is mainly
believed to be associated with its repressive effect on the
Ink4a/Arf tumor suppressor locus and p53/p21 pathway,
both of which plays critical roles in the onset of cellular
senescence in many different types of human somatic cells
[29,30]. Therefore, Bmi1 may be associated with tumori-
genesis via dysregulation of multiple growth regulatory
pathways. AKT was selected in this study because AKT
activity is constitutively high in many cancers [31-33] and
a recent study has suggested that Bmi1 regulates AKT activ-
ity in breast cancer cells [34,35]. As showing in Figure 4A,
the expression of Bmi1 and pAKT was both notably higher
in SASVO3 cells compared to the SAS-GFP cells. On the
other hand, the expression levels of p14 and p21 were
reduced in the SASVO3 cells. However, no significant dif-
ference was observed for the expression of CD133, CD44,
Nanog, and Oct-4 in SAS-GFP and SASVO3 cells (data not
shown). Further, to determine whether expression of
Bmi1 is correlated with tumorigenicity in vivo, we per-
formed a histological examination that detected Bmi1 in
the mouse tumor xenografts. Diffuse cytoplasmic Bmi1
staining was detected in the dorsal tissue of the tumor
Expression of genes unique to cancer stem cells and/or malignant cells Figure 4
Expression of genes unique to cancer stem cells and/or malignant cells. (A) Cell extracts from SAS-GFP and SASVO3 
were analyzed for the expression of Bmi1, p14Arf, p21, pAKT, AKT and β-catenin by Western blotting. GAPDH served as a 
loading control, was reproducibly similar in all experiments. Results shown are from one of three similar experiments. (B) The 
expression of Bmi1 protein in mouse xenografts tissue from the dorsal tumor area was detected by IHC.Journal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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SASVO3 xenografts, but not in dorsal tissue of the SAS-
GFP xenografts (Figure 4B).
Enhanced metastasis in vivo by SASVO3 cells
As presented earlier, SASVO3 cells display enhanced
migration and invasion in vitro (see Figure 2), which sug-
gests that SASVO3 may have increased metastatic poten-
tial  in vivo. For epithelial malignancies, the epithelial
mesenchymal transition (EMT) is considered to be a cru-
cial event in the metastatic process, and β-catenin is
known to be involved in induction of the EMT [36]. To
investigate whether SASVO3 cells may have acquired
increased metastasis potential, the expression of β-catenin
and the ability to induce pulmonary metastasis were
examined. As shown in Figure 4A, increased β-catenin
expression was detected in lysate from SASVO3 cells, but
not in lysate from SAS-GFP cells. Furthermore, pulmonary
metastasis was detected in one out of three nude mice that
were injected with SASVO3 cells into tail vein (Figure 5,
left), but none was detected in the three mice injected with
SAS-GFP cells. Liver metastasis was also detected in one
out of three mice that were injected with SASVO3 cells
into the spleen, but none was detected in the three mice
injected with SAS-GFP cell (data not shown). Histological
examination indicated that there was a significant increase
in pulmonary metastatic colonization and angiogenesis
in the mice injected with SASVO3 (Figure 5, middle).
Finally, the pulmonary metastatic tissue displayed strong
intranuclear and cytoplasmic Bmi1 staining (Figure 5,
right), which is in accordance with the IHC results from
the dorsal tumor tissues shown in Figure 4. Together,
these results demonstrated that SASVO3 cells displayed
increased capability for metastasis in vivo.
Discussion
In this study, we have demonstrated that serial transplan-
tation of a human HNSCC cancer cell line in nude mice
can enrich the malignant subpopulation. Furthermore, we
provide evidence that the increased malignant potential
in the xenograft-derived cells appears to be attributable to
the enrichment of a subpopulation that displays an
increased expression of Bmi1 and pAKT (Figure 3 and 4),
but not CD133, CD44, Nanog, and Oct-4 (unpublished
results). The highly tumorigenic cancer stem cells isolated
by sphere assay from HNSCC cell lines were previously
reported to display an increased expression of CD133,
Nanog, and Oct-4 [17]. At present, it is not known why
the markers expressed in the subpopulation of serial
xenograft-derived SASVO3 differ from the ones expressed
in the highly tumorigenic cancer stem cells isolated by
sphere assay. Serial passages of cell lines frequently lead to
change of characteristics and acquisition of genetic aberra-
tions, resulting in the selection of atypical clones [3,37].
Therefore, the markers on malignant cells of established
cell lines may differ from cancer stem cells in original
tumors. It is possible that the sphere assay may enrich all
of highly malignant cancer stem cells that are present in
the established cell lines, while the serial xenotransplanta-
tion method may enrich only the original cancer stem
cells that produce tumors in vivo.
Pulmonary metastasis generated by SASVO3 Figure 5
Pulmonary metastasis generated by SASVO3. SASVO3 cells were injected into the tail vein and the mice were sacri-
ficed after 90 days to detect lung colonization by tumors. Gross morphology is shown by an illuminating device (left). Histolog-
ical analysis of the lungs for metastatic lesions was performed by H&E staining (middle). The expression of Bmi1 in a pulmonary 
metastatic tumor was detected by IHC (right).Journal of Biomedical Science 2009, 16:100 http://www.jbiomedsci.com/content/16/1/100
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It is interesting to note that the xenograft-derived SASVO3
cells also display increased capability for metastasis (Fig-
ure 5), which suggests that the enriched subpopulation
may be also highly capable of metastasis. Therefore, the
establishing of a highly malignant HNSCC cell line by the
xenograft model should be an ideal method for identify-
ing within tumors that subpopulation of cells displaying
cancer stem cell properties. Since cancer stem cells have
been suspected to underlie the incurable and relapsing
nature of many metastatic tumors, our establishment of a
highly malignant cell line should pave the road for the
future development of new therapies that target these can-
cer stem cells. In addition, these xenograft-derived cells
should be very useful when studying the molecular proc-
esses and pathways that are unique to the cancer stem
cells.
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